tiprankstipranks
Advertisement
Advertisement

KAPA Stock Latest News

Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12
RatingsPantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12
2d ago
KAPA
Kairos Pharma, Bayer partner on prostate cancer therapy
PremiumCompany Announcements
Kairos Pharma, Bayer partner on prostate cancer therapy
7d ago
8K
KAPA
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
PremiumThe Fly
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
7d ago
KAPA
Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105
PremiumThe Fly
Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105
14d ago
KAPA
Kairos Pharma Shareholders Approve Reverse Split, Governance Measures
PremiumCompany Announcements
Kairos Pharma Shareholders Approve Reverse Split, Governance Measures
29d ago
8K
KAPA
Kairos Pharma outlines mid-year oncology pipeline and funding plans
PremiumCompany AnnouncementsKairos Pharma outlines mid-year oncology pipeline and funding plans
2M ago
8K
KAPA
Kairos Pharma issues letter from CEO that recaps year, details plans for 2026
Premium
The Fly
Kairos Pharma issues letter from CEO that recaps year, details plans for 2026
2M ago
KAPA
Kairos Pharma Highlights Clinical Programs at LD Micro
Premium
Company Announcements
Kairos Pharma Highlights Clinical Programs at LD Micro
2M ago
8K
KAPA
Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
PremiumRatings
Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
5M ago
KAPA
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
PremiumCompany Announcements
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
5M ago
8K
KAPA
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
PremiumThe Fly
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
5M ago
KAPA
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
PremiumThe Fly
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
5M ago
KAPA
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
PremiumCompany AnnouncementsKairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
5M ago
8K
KAPA
Kairos Pharma files $75M mixed securities shelf
Premium
The Fly
Kairos Pharma files $75M mixed securities shelf
7M ago
KAPA
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
Premium
Ratings
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
8M ago
KAPA
Kairos Pharma Approves RSUs and Cash Bonuses
PremiumCompany Announcements
Kairos Pharma Approves RSUs and Cash Bonuses
10M ago
8K
KAPA
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
PremiumRatings
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
10M ago
KAPA
Kairos Pharma to Present at ESMO Congress 2025
PremiumCompany Announcements
Kairos Pharma to Present at ESMO Congress 2025
10M ago
8K
KAPA
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
PremiumRatings
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
10M ago
KAPA
Kairos Pharma Reports Positive Phase 2 Trial Results
PremiumCompany AnnouncementsKairos Pharma Reports Positive Phase 2 Trial Results
10M ago
8K
KAPA
Kairos Pharma announces interim efficacy analysis of ENV105
Premium
The Fly
Kairos Pharma announces interim efficacy analysis of ENV105
10M ago
KAPA
Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation
Premium
Ratings
Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation
10M ago
KAPA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >